Prediction of the very early occurrence of HCC right after DAA therapy for HCV infection.
Yoshihiko OokaKanda MihoObi ShuntaroMasato NakamuraSadahisa OgasawaraEiichiro SuzukiShin YasuiTetsuhiro ChibaMakoto AraiTatsuo KandaHitoshi MaruyamaOsamu YokosukaNaoya KatoHitoshi MochizukiMasao OmataPublished in: Hepatology international (2018)
SOF regimens for HCV also have very high rates of SVR 12 in the post-market distribution. The appearance of imaging "dysplastic nodule" was an associated factor of 1-year HCC occurrence and recurrence. To investigate existence of "dysplastic nodule" by imaging surveillance before DAA treatment is useful to detect high-risk patients of very early HCC occurrence and recurrence and it should be performed.